key: cord-0032133-uxja1rvk authors: Connolly, Caoilfhionn M; Frey, Sarah; Chiang, Teresa Po-Yu; Teles, Mayan; Alejo, Jennifer L; Albayda, Jemima; Shah, Ami A; Werbel, William A; Segev, Dorry L; Christopher-Stine, Lisa; Paik, Julie J title: Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease date: 2022-05-18 journal: Rheumatology (Oxford) DOI: 10.1093/rheumatology/keac298 sha: e1e08efec3fff1defbfb7630ec9a8dbceef41a28 doc_id: 32133 cord_uid: uxja1rvk nan Despite the morbidity and mortality associated with COVID-19 infection, vaccine hesitancy remains an ongoing clinical challenge for rheumatologists worldwide. As the SARS-CoV-2 virus has evolved, it has become apparent that additional vaccine doses are required to augment vaccine-induced protection (1, 2) . We previously reported that two-dose SARS-CoV-2 vaccination is well-tolerated among patients with rheumatic and musculoskeletal diseases (RMD) (3) . Immune recall evokes a strong immune response following a third vaccine dose (D3) (2) , raising concern that additional immunological priming post-D3 could negatively impact disease activity among RMD patients. There is currently a paucity of data on the safety of D3 among RMD patients, thus, we sought to evaluate disease flare and post-vaccination reactions (reactogenicity) following third dose SARS-CoV-2 vaccination in RMD patients. Adult RMD patients who received three-dose SARS-CoV-2 vaccination (two-dose mRNA followed by single mRNA or adenoviral dose) completed questionnaires detailing local and systemic reactions experienced within 7 days of D3. Local reactions such as pain, redness, and swelling, as well as systemic reactions including fever, fatigue, headaches, chills, vomiting, diarrhea, and myalgia were captured using an ordinal scale; these were graded per their impact on daily activity including "no interference with daily activity," "some interference with daily activity," and "prevention of daily activity". One month following D3, participants completed an online questionnaire pertaining to incidence and prior history of flare, incident flare as well as symptoms, duration, and treatment; flare events were qualified as flares requiring treatment by a physician as previously described (3) . Associations between participant characteristics and flare were examined using logistic regression. All tests were two-sided with an α level of 0.05; significant associations on univariate analysis were included in multivariable analysis. The most common local and systemic reactions included injection site pain (87%) and fatigue (75%); most did not interfere with daily activity (Supplementary Figure S1 ). Reports of reactions that prevented daily 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 activities were uncommon, with fatigue (13%) and myalgia (7%) most frequently reported (Supplementary Table S1 ). There were no post-vaccination reactions requiring hospitalization. Limitations of this study include lack of granularity on baseline disease control and physician verification of flare. In addition, the use of survey data may result in both recall and selection bias, while it may also underestimate severe outcomes. Strengths include a large, national sample with novel findings addressing an area in which there is currently a large knowledge deficit. We provide novel data on post-D3 safety in a large cohort of RMD patients. Consistent with findings following two-dose SARS-CoV-2 vaccination in both centre-based (4-6) and population-based studies (7), D3 was well tolerated with low rates of flare. There was an association between flare and younger age, with 6% higher odds of flare per decrease in year. While flare prior to vaccination and following twodose vaccination was associated with flare following D3 on univariate analysis, these did not reach significance on multivariable analysis. Furthermore, we previously reported an association of prevaccination COVID-19 infection and flare (3), but did not observe a relationship in this analysis which has been limited by small size; these warrant additional evaluation in larger cohorts. In addition, modulation of peri-vaccination immunosuppression was not associated with increased rate of flare, thereby providing reassurance regarding this strategy to augment the vaccine-response among our vulnerable patients. Our findings emphasise the safety of SARS-CoV-2 vaccines among RMD patients. Waning protection conferred by mRNA vaccines reinforces the importance of additional doses to improve protection (8); our data will help address vaccine hesitancy relating additional vaccine doses in RMD patients. This study was approved by the Johns Hopkins Institutional Review Board (IRB00248540). Participants gave informed consent to participate before taking part in this study. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 The denominators for these categories differ from the total N as 3 participants selected 'prefer not to answer' for race, 32 did not answer 'flare prior to vaccination Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis and inflammatory bowel disease associated arthritis 5 Overlap denotes participants who selected >1 diagnostic categories including inflammatory arthritis, SLE, Sjogrens, vasculitis, myositis, or systemic sclerosis upadacitinib, and ustekinumab 8 Intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin Denotes cDMARD and biologic and/or glucocorticoid, or biologic and glucocorticoid A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine Disease Flare and Reactogenicity in Patients With Rheumatic and Musculoskeletal Diseases Following Two-Dose SARS-CoV-2 Messenger RNA Vaccination Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States We would like to acknowledge the contributions of: Brian J. Boyarsky MD, PhD, Jake A. Ruddy BS, and Jacqueline M. Garonzik-Wang MD PhD. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or